Chengdu Olymvax Biopharmaceuticals Inc. A
医疗健康 · 生物科技
Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use in China. The company offers absorbed tetanus vaccine, group a and group c products; and haemophilus influenzae type b products. The company was founded in 2009 and is based in Chengdu, China.
MARKET 市值 17.99B CNY PE 317.0x
52W ¥17.34 – ¥44.9
EODHD · Q 2026-03-31 · 同步 2026-07-14
QUALITY PEG — 营收 YoY 80.4%
▲ ROE 6.0% 营业利润率 17.0% 净利润率 7.3%